[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2003051837A3 - Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr) - Google Patents

Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr) Download PDF

Info

Publication number
WO2003051837A3
WO2003051837A3 PCT/EP2002/014344 EP0214344W WO03051837A3 WO 2003051837 A3 WO2003051837 A3 WO 2003051837A3 EP 0214344 W EP0214344 W EP 0214344W WO 03051837 A3 WO03051837 A3 WO 03051837A3
Authority
WO
WIPO (PCT)
Prior art keywords
gpcr
tetrahydrocarbozole
ligands
derivatives
protein coupled
Prior art date
Application number
PCT/EP2002/014344
Other languages
German (de)
French (fr)
Other versions
WO2003051837A2 (en
WO2003051837A8 (en
Inventor
Marcus Koppitz
Hans Peter Muhn
Ken Shaw
Holger Hess-Stumpp
Klaus Paulini
Original Assignee
Zentaris Gmbh
Marcus Koppitz
Hans Peter Muhn
Ken Shaw
Holger Hess-Stumpp
Klaus Paulini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10164564A external-priority patent/DE10164564B4/en
Priority to BR0214958-3A priority Critical patent/BR0214958A/en
Priority to RU2004121776/04A priority patent/RU2319692C2/en
Priority to EP02796648A priority patent/EP1453803A2/en
Application filed by Zentaris Gmbh, Marcus Koppitz, Hans Peter Muhn, Ken Shaw, Holger Hess-Stumpp, Klaus Paulini filed Critical Zentaris Gmbh
Priority to UA20040503889A priority patent/UA77025C2/en
Priority to MXPA04005768A priority patent/MXPA04005768A/en
Priority to IL16162602A priority patent/IL161626A0/en
Priority to HU0500014A priority patent/HUP0500014A3/en
Priority to HR20040609A priority patent/HRP20040609A2/en
Priority to KR10-2004-7009212A priority patent/KR20040072657A/en
Priority to NZ533430A priority patent/NZ533430A/en
Priority to CA002468880A priority patent/CA2468880A1/en
Priority to JP2003552724A priority patent/JP2005518375A/en
Priority to AU2002361430A priority patent/AU2002361430B2/en
Publication of WO2003051837A2 publication Critical patent/WO2003051837A2/en
Publication of WO2003051837A3 publication Critical patent/WO2003051837A3/en
Publication of WO2003051837A8 publication Critical patent/WO2003051837A8/en
Priority to NO20042198A priority patent/NO326692B1/en
Priority to IL192991A priority patent/IL192991A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to novel tetrahydrocarbozole derivatives acting as ligands for G-protein coupled receptors (GPCR), especially as antagonists of gonadotropin-releasing hormone (GnRH). The invention also relates to a pharmaceutical composition containing said novel tetrahydrocarbozole derivatives, and to a method for producing the same. Furthermore, the invention relates to the administration of tetrahydrocarbozole derivatives for the treatment of pathological conditions mediated by GPCR, especially for the inhibition of GnRH, to mammals, especially humans, requiring such treatment, and to the use of tetrahydrocarbozole derivatives for producing a pharmaceutical agent for treating pathological conditions mediated by GPCR, especially for the inhibition of GnRH.
PCT/EP2002/014344 2001-12-14 2002-12-16 Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr) WO2003051837A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
AU2002361430A AU2002361430B2 (en) 2001-12-14 2002-12-16 Tetrahydrocarbozole derivatives as ligands for G-protein coupled receptors (GPCR)
HR20040609A HRP20040609A2 (en) 2001-12-14 2002-12-16 Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr)
EP02796648A EP1453803A2 (en) 2001-12-14 2002-12-16 Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr)
NZ533430A NZ533430A (en) 2001-12-14 2002-12-16 Tetrahydrocarbozole derivatives as ligands for G-protein coupled receptors (GPCR)
UA20040503889A UA77025C2 (en) 2001-12-14 2002-12-16 Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr), a pharmaceutical composition and a method for preparation of compounds
MXPA04005768A MXPA04005768A (en) 2001-12-14 2002-12-16 Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr).
IL16162602A IL161626A0 (en) 2001-12-14 2002-12-16 Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr)
HU0500014A HUP0500014A3 (en) 2001-12-14 2002-12-16 Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr) and pharmaceutical compositions containing them
KR10-2004-7009212A KR20040072657A (en) 2001-12-14 2002-12-16 Tetrahydrocarbazole derivatives as ligands for G-protein coupled receptors(GPCR)
BR0214958-3A BR0214958A (en) 2001-12-14 2002-12-16 Tetrahydrocarbazole derivatives as g-protein coupled receptor ligands (gpcr)
RU2004121776/04A RU2319692C2 (en) 2001-12-14 2002-12-16 Derivatives of tetrahydrocarbazole, method for preparing tetrahydrocarbazole (variants), their using (variants) and pharmaceutical composition possessing activity of antagonist of gonadotropin-releasing hormone (variants)
CA002468880A CA2468880A1 (en) 2001-12-14 2002-12-16 Tetrahydrocarbazole derivatives as ligands for g-protein coupled receptors (gpcr)
JP2003552724A JP2005518375A (en) 2001-12-14 2002-12-16 Tetrahydrocarbazole derivatives as ligands for G protein coupled receptors (GPCRs)
NO20042198A NO326692B1 (en) 2001-12-14 2004-05-26 Tetrahydrocarbazole derivatives as ligands for G-protein coupled receptors (GPCRs), their use and pharmaceutical preparations containing these
IL192991A IL192991A0 (en) 2001-12-14 2008-07-23 Use of tetrahydrocarbazole derivatives for the manufacture of medicanents for treating gonadotropin-releasing hormone

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10164564.3 2001-12-14
DE10164564A DE10164564B4 (en) 2001-12-14 2001-12-14 Tetrahydrocarbazole derivatives as ligands for G-protein coupled receptors (GPCR)
US34187801P 2001-12-21 2001-12-21
US60/341,878 2001-12-21

Publications (3)

Publication Number Publication Date
WO2003051837A2 WO2003051837A2 (en) 2003-06-26
WO2003051837A3 true WO2003051837A3 (en) 2004-02-26
WO2003051837A8 WO2003051837A8 (en) 2004-05-06

Family

ID=26010882

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/014344 WO2003051837A2 (en) 2001-12-14 2002-12-16 Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr)

Country Status (17)

Country Link
EP (1) EP1453803A2 (en)
JP (1) JP2005518375A (en)
CN (1) CN100500654C (en)
AR (1) AR037863A1 (en)
AU (1) AU2002361430B2 (en)
BR (1) BR0214958A (en)
CA (1) CA2468880A1 (en)
HR (1) HRP20040609A2 (en)
HU (1) HUP0500014A3 (en)
IL (2) IL161626A0 (en)
MX (1) MXPA04005768A (en)
NO (1) NO326692B1 (en)
NZ (1) NZ533430A (en)
PL (1) PL373400A1 (en)
RU (1) RU2319692C2 (en)
TW (1) TWI246423B (en)
WO (1) WO2003051837A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1791592B (en) * 2003-05-19 2012-07-04 Irm责任有限公司 Immunosuppressant compounds and compositions
BRPI0411085A (en) * 2003-06-10 2006-07-25 Smithkline Beecham Corp compound, pharmaceutical composition, use of a compound, and methods for the treatment or prophylaxis of oncogenic viruses, and conditions or disorders due to hpv infection
WO2005026112A2 (en) * 2003-09-12 2005-03-24 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
US20060074124A1 (en) 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
PL1732892T3 (en) * 2004-03-26 2009-03-31 Hoffmann La Roche Tetrahydrocarbazoles and derivatives
DE102004033902A1 (en) * 2004-07-14 2006-02-16 Zentaris Gmbh New tetrahydrocarbazole compounds are neurokinin-1 receptor antagonists useful to treat or prevent e.g. pubertas praecox, hirsutism, polycystic ovary syndrome, hormone dependent neoplastic diseases and Alzheimer's disease
RU2430088C2 (en) * 2004-07-14 2011-09-27 Центарис Гмбх Tetrahydrocarbazole derivatives and pharmaceutical composition based on said derivatives
SI1833791T1 (en) * 2004-12-27 2011-11-30 Actelion Pharmaceuticals Ltd 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
CN101203491A (en) * 2005-06-24 2008-06-18 伊莱利利公司 Tetrahydrocarbazole derivatives used as androgen receptor modifier
EP2051962B1 (en) * 2006-08-07 2011-10-26 Actelion Pharmaceuticals Ltd. (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
EP1967202A1 (en) * 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
EP1988098A1 (en) 2007-04-27 2008-11-05 AEterna Zentaris GmbH Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors
EP2095818A1 (en) 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
SI2558447T1 (en) 2010-03-22 2015-01-30 Actelion Pharmaceuticals Ltd. 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MX338516B (en) 2011-04-14 2016-04-20 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators.
MY179356A (en) 2014-03-17 2020-11-05 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
KR20160133536A (en) 2014-03-18 2016-11-22 액테리온 파마슈티칼 리미티드 Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2017046125A1 (en) 2015-09-15 2017-03-23 Actelion Pharmaceuticals Ltd Crystalline forms

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2425767A1 (en) * 1973-06-02 1975-01-09 Pfizer 3-ALKYL-9-AMINOALKYL-1,2,3,4-TETRAHYDROCARBAZOLES AND THEIR USE IN MEDICINAL PRODUCTS
EP0239306A2 (en) * 1986-03-27 1987-09-30 Merck Frosst Canada Inc. Tetrahydrocarbazole esters
EP0679642A1 (en) * 1994-04-28 1995-11-02 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
WO1998055116A1 (en) * 1997-06-05 1998-12-10 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG25793A3 (en) * 1973-07-18 1978-12-12 Schering Aktiengesellschaft METHOD FOR OBTAINING CARBAZOLE DERIVATIVES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2425767A1 (en) * 1973-06-02 1975-01-09 Pfizer 3-ALKYL-9-AMINOALKYL-1,2,3,4-TETRAHYDROCARBAZOLES AND THEIR USE IN MEDICINAL PRODUCTS
EP0239306A2 (en) * 1986-03-27 1987-09-30 Merck Frosst Canada Inc. Tetrahydrocarbazole esters
EP0679642A1 (en) * 1994-04-28 1995-11-02 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
WO1998055116A1 (en) * 1997-06-05 1998-12-10 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAVIES D J ET AL: "Mapping the melatonin receptor. 5. Melatonin agonists and antagonists derived from tetrahydrocyclopent[b]indoles, tetrahydrocarbazoles and hexahydrocyclohept[b]indoles", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 41, no. 4, 1998, pages 451 - 467, XP002215114, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
AU2002361430B2 (en) 2007-09-13
CN100500654C (en) 2009-06-17
PL373400A1 (en) 2005-08-22
EP1453803A2 (en) 2004-09-08
NO326692B1 (en) 2009-02-02
NO20042198L (en) 2004-07-09
RU2004121776A (en) 2005-05-10
IL192991A0 (en) 2011-08-01
TWI246423B (en) 2006-01-01
MXPA04005768A (en) 2004-09-10
TW200305405A (en) 2003-11-01
CN1599720A (en) 2005-03-23
WO2003051837A2 (en) 2003-06-26
JP2005518375A (en) 2005-06-23
NZ533430A (en) 2005-12-23
HRP20040609A2 (en) 2005-06-30
BR0214958A (en) 2004-12-28
AU2002361430A1 (en) 2003-06-30
HUP0500014A3 (en) 2010-06-28
HUP0500014A2 (en) 2005-04-28
AR037863A1 (en) 2004-12-09
RU2319692C2 (en) 2008-03-20
IL161626A0 (en) 2004-09-27
WO2003051837A8 (en) 2004-05-06
CA2468880A1 (en) 2003-06-26

Similar Documents

Publication Publication Date Title
WO2003051837A3 (en) Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr)
WO2003045918A8 (en) Piperidine-based mch antagonists for treatment of obesity and cns disorders
WO2004105781A3 (en) Stabilized pharmaceutical peptide compositions
WO2003097608A3 (en) Opioid and opioid-like compounds and uses thereof
WO2003027076A3 (en) 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity
HK1054333A1 (en) Heteroaryl urea neuropeptide y y5 receptor antagonists
WO2003010159A8 (en) Piperidine derivatives as nmda receptor antagonists
UA77025C2 (en) Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr), a pharmaceutical composition and a method for preparation of compounds
MXPA04000707A (en) Substituted urea neuropeptide y y5 receptor antagonists.
MXPA03009439A (en) 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity.
DE60231341D1 (en) FLUOROUS AND SULFONYLAMINE-BASED, 3,6-DISUBSTITUIERPTORANTAGONISTS
MXPA04002583A (en) Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity.
SE0100568D0 (en) Compounds
MY141559A (en) Triazole derivatives as tachykinin receptor antagonists
MXPA04003858A (en) Mch antagonists for the treatment of obesity.
WO2006044504A8 (en) Cgrp receptor antagonists
NO20070248L (en) Methods for the preparation of gonadotropin-releasing hormone receptor antagonists
WO2001096307A3 (en) Cycloalkyl alkanoic acids as integrin receptor antagonists
WO2004005262A8 (en) New neuropeptide y y5 receptor antagonists
HK1044483A1 (en) Il-8 receptor antagonists
AU2002368152A1 (en) 3,6-disubstituted azabicyclo (3.1.0)hexane derivatives useful as muscarinic receptor antagonists
EP1398029A8 (en) NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
JP2004511522A5 (en)
ZA200305803B (en) Prevention of diabetes by administration of GnRH antagonists.
WO2007006732A8 (en) Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002796648

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 161626

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 373400

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 2004/03352

Country of ref document: ZA

Ref document number: 200403352

Country of ref document: ZA

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 26/2003 UNDER (30) REPLACE "101 64 564, 14 DECEMBER 2001 (14.12.2001), DE" BY "101 64 564.3, 14 DECEMBER 2001 (14.12.2001), DE"

WWE Wipo information: entry into national phase

Ref document number: 2002361430

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2468880

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 20028241487

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 00779/KOLNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 533430

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/005768

Country of ref document: MX

Ref document number: 2003552724

Country of ref document: JP

Ref document number: 1020047009212

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: P20040609A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: DZP2004000186

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2004121776

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2002796648

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 1-2004-500887

Country of ref document: PH

WWP Wipo information: published in national office

Ref document number: 533430

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 533430

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 192991

Country of ref document: IL